Demographic characteristics, number of CD4+T cells in 1 mL of blood collected from patients with AIHA and healthy volunteers
| Sample ID . | Sex . | Age, y . | Number of CD4+× 103/L . | % of FoxP3–CD39+/CD4+ . | Hgb . | Indirect bilirubin . | LDH . | Haptoglobin . | History . | Treatment . |
|---|---|---|---|---|---|---|---|---|---|---|
| AIHA-1 | F | 82 | 8 364 | 8.09 | 3.9 | 7.7 | 1396 | <20 | CLL and severe AIHA | High-dose steroids, IVIG, and rituximab |
| AIHA-2 | M | 67 | 16 202 | 3.6 | 6.8 | 2.2 | 352 | <20 | Systemic mastocytosis, cytopenias, and Evans syndrome | High-dose steroids, IVIG, and rituximab |
| AIHA-3 | M | 59 | 16 855 | 5.29 | 3.9 | 3.9 | 2801 | <10 | Diabetes type 2, severe AIHA mixed warm and cold autoantibodies | High-dose steroids, plasma exchange, and rituximab |
| AIHA-4 | M | 76 | 3 141 | 31.5 | 6.6 | 2.3 | 350 | <20 | Follicular lymphoma, hemolysis, and warm autoantibodies | Rituximab |
| AIHA-5 | M | 71 | 11 056 | 10.4 | 3.1 | 2.7 | 953 | <20 | CLL and AIHA | High-dose steroids |
| AIHA-6 | M | 58 | 5 123 | 30.4 | 5.8 | 0.7 | 665 | <20 | AITL and AIHA | High-dose steroids, etoposide, and belinostat for AITL |
| AIHA-7 | M | 4 | 14 612 | 12.6 | 5.2 | 1 | 710 | Dilated cardiomyopathy, pure red cell aplasia, and AIHA | High-dose steroids and rituximab | |
| AIHA-8 | M | 84 | 9 736 | 10.11 | 8.3 | 1.8 | 669 | <20 | CLL, warm and cold autoantibodies, and severe anemia | High-dose steroids |
| AIHA-9 | M | 21 | 9 805 | 7.15 | 6.3 | 2.1 | 403 | <20 | Evans syndrome, warm AIHA, and CLL | High-dose steroids, IVIG, rituximab, and cytoxan |
| Healthy-1 | M | 37 | 46 116 | 0.21 | ||||||
| Healthy-2 | F | 36 | 46 202 | 3.91 | ||||||
| Healthy-3 | F | 23 | 42 875 | 2.3 | ||||||
| Healthy-4 | F | 27 | 24 138 | 1.59 | ||||||
| Healthy-5 | F | 24 | 45 431 | 2.14 | ||||||
| Healthy-6 | F | 42 | 63 190 | 1.45 | ||||||
| Healthy-7 | F | 62 | 66 387 | 3.56 | ||||||
| Healthy-8 | F | 71 | 47 738 | 4.3 | ||||||
| Healthy-9 | M | 71 | 52 723 | 0.9 | ||||||
| Healthy-10 | M | 55 | 70 446 | 14.9 | ||||||
| Healthy-11 | M | 51 | 110 017 | 3.4 | ||||||
| Healthy-12 | F | 65 | 111 893 | 13 | ||||||
| Healthy-13 | M | 63 | 63 711 | 3.03 | ||||||
| Healthy-14 | M | 50 | 75 011 | 3.65 | ||||||
| Healthy-15 | M | 63 | 57 511 | 7.81 |
| Sample ID . | Sex . | Age, y . | Number of CD4+× 103/L . | % of FoxP3–CD39+/CD4+ . | Hgb . | Indirect bilirubin . | LDH . | Haptoglobin . | History . | Treatment . |
|---|---|---|---|---|---|---|---|---|---|---|
| AIHA-1 | F | 82 | 8 364 | 8.09 | 3.9 | 7.7 | 1396 | <20 | CLL and severe AIHA | High-dose steroids, IVIG, and rituximab |
| AIHA-2 | M | 67 | 16 202 | 3.6 | 6.8 | 2.2 | 352 | <20 | Systemic mastocytosis, cytopenias, and Evans syndrome | High-dose steroids, IVIG, and rituximab |
| AIHA-3 | M | 59 | 16 855 | 5.29 | 3.9 | 3.9 | 2801 | <10 | Diabetes type 2, severe AIHA mixed warm and cold autoantibodies | High-dose steroids, plasma exchange, and rituximab |
| AIHA-4 | M | 76 | 3 141 | 31.5 | 6.6 | 2.3 | 350 | <20 | Follicular lymphoma, hemolysis, and warm autoantibodies | Rituximab |
| AIHA-5 | M | 71 | 11 056 | 10.4 | 3.1 | 2.7 | 953 | <20 | CLL and AIHA | High-dose steroids |
| AIHA-6 | M | 58 | 5 123 | 30.4 | 5.8 | 0.7 | 665 | <20 | AITL and AIHA | High-dose steroids, etoposide, and belinostat for AITL |
| AIHA-7 | M | 4 | 14 612 | 12.6 | 5.2 | 1 | 710 | Dilated cardiomyopathy, pure red cell aplasia, and AIHA | High-dose steroids and rituximab | |
| AIHA-8 | M | 84 | 9 736 | 10.11 | 8.3 | 1.8 | 669 | <20 | CLL, warm and cold autoantibodies, and severe anemia | High-dose steroids |
| AIHA-9 | M | 21 | 9 805 | 7.15 | 6.3 | 2.1 | 403 | <20 | Evans syndrome, warm AIHA, and CLL | High-dose steroids, IVIG, rituximab, and cytoxan |
| Healthy-1 | M | 37 | 46 116 | 0.21 | ||||||
| Healthy-2 | F | 36 | 46 202 | 3.91 | ||||||
| Healthy-3 | F | 23 | 42 875 | 2.3 | ||||||
| Healthy-4 | F | 27 | 24 138 | 1.59 | ||||||
| Healthy-5 | F | 24 | 45 431 | 2.14 | ||||||
| Healthy-6 | F | 42 | 63 190 | 1.45 | ||||||
| Healthy-7 | F | 62 | 66 387 | 3.56 | ||||||
| Healthy-8 | F | 71 | 47 738 | 4.3 | ||||||
| Healthy-9 | M | 71 | 52 723 | 0.9 | ||||||
| Healthy-10 | M | 55 | 70 446 | 14.9 | ||||||
| Healthy-11 | M | 51 | 110 017 | 3.4 | ||||||
| Healthy-12 | F | 65 | 111 893 | 13 | ||||||
| Healthy-13 | M | 63 | 63 711 | 3.03 | ||||||
| Healthy-14 | M | 50 | 75 011 | 3.65 | ||||||
| Healthy-15 | M | 63 | 57 511 | 7.81 |
Frequency of CD39SP cells with phenotype CD4+CD39+CD73–FoxP3–CD25– was calculated. Laboratory evaluation of patients with AIHA. AITL, angioimmunoblastic T-cell lymphoma; CLL, chronic lymphocytic leukemia; F, female; Hgb, hemoglobin; IVIG, IV immunoglobulin; LDH, lactate dehydrogenase; M, male.